/PRNewswire/ -- Micross Components, a leading global provider of distributed and specialty electronic solutions, is pleased to announce its participation in the "Drive for Innovation" tour, sponsored by Avnet Express and UBM Electronics. Included as a "pit stop" during the tour's recent swing through Central Florida, Micross was selected because of its role in powering innovation by companies driving technological advancements across defense, space, medical and other high-reliability industries.
/PRNewswire/ -- Today Divine Skin (OTC Bulletin Board: DSKX) released preliminary revenue figures for the fourth quarter, $3.1 million, up 63 percent over the same quarter of 2010 and up 48 percent over the third quarter of 2011. For the year 2011, revenue totaled $9.6 million, up 78 percent over 2010.
Event to explore lessons learned from FDA 483s in tracks focused on Biotech, Oral Solid Dosage Processing and Containment, and Process Validation
RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, is highlighting two new allografts and introducing a public education website at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Francisco this week. BioAdapt™ DBM, a sterile, room temperature DBM implant that provides a contoured fit to bony defects; Fresh-stored Osteochondral Humeral Head, an allograft that enables surgeons to resurface osteochondral defects in a single procedure; and AllograftInfo.com, an informational website to educate patients and the general public about allograft tissue, will be showcased at the RTI Biologics exhibit at booth 4137 (Hall E) during the AAOS meeting at the Moscone Center.
As Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), continues to vet investment banks to assist with its capital raise, investors remain optimistic on the returns that new biotech firms can bring. A recent report indicates that venture capital investments in biotech increased by 22 percent to $4.7 billion last year.
/PRNewswire/ -- During a ceremony today at the National Biodiesel Conference in Orlando, Hino Trucks was recognized by the National Biodiesel Board with the 2012 "Eye on Biodiesel Impact Award."
Amyris to Provide Update Call on February 9, 2012 and Report 2011 Fourth Quarter and Year End Financial Results on February 27, 2012
/PRNewswire/ -- BioStorage Technologies, a global provider of comprehensive sample management solutions, biomaterial storage and cold chain logistics for the bioscience industry, will host its Global Sample Management Benchmarking Workshop at Partnerships in Clinical Trials on Tuesday, March 6, 2012 at the Marriott World Center in Orlando, Florida.
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that an article was published in HemOnc Today, reporting on the promise of Biovest’s BiovaxID® personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma, an incurable form of blood cancer.
Rainbow Biosciences, the biotech division of Rainbow Coral Corp. (OTCBB:RBCC), announced today that it’s on the cusp of a major breakthrough in its business relationship with n3D Biosciences.
All signs point to emerging biotech company Rainbow Coral Corp. (OTCBB:RBCC) finding its feet in biotechnology at exactly the right time: The biotech industry is off to a great start in the early stages of 2012.
—New Company Developing Therapeutics Targeting Epilepsy and Related Diseases—, —Noted Epilepsy Expert Dr. Steven Schachter Joins as Chair of SAB—,
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that OneMedPlace, a biotechnology-focused research and media organization engaged by Biovest, has initiated research coverage on Biovest. The new report, issued this week by Dr. Malini Chatterjee, Ph.D., discusses the anticipated regulatory pathway and market opportunity for BiovaxID®, Biovest’s personalized cancer vaccine for the treatment of certain B-cell subtypes of non-Hodgkin’s lymphoma (NHL).
Patient Treatments of Bulging and Herniated Discs Show Promising Results, Closing of License Grant Scheduled for March 2012,
Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that the initial clinical data from the safety study for Symphony™ was presented by Renzo Cecere, M.D., FRCSC, FACS, Associate Professor of Surgery at McGill University, during the late-breaking clinical trials session at the Society of Thoracic Surgeons (STS) 2012 Annual Meeting in Fort Lauderdale, Florida.
Just Released: The Sex Drive Solution for Women by Jennifer Landa, M.D., Chief Medical Officer of BodyLogicMD.
/PRNewswire/ -- rED Cap™, the proprietary, web-based clinical trial data management software developed by BioStat International, Inc. (BSI), recently received trademark status.
Cutting-edge stem cell research is producing new breakthroughs that could potentially revolutionize the treatment of currently incurable diseases from cancer to brain injuries to headaches. Rainbow Coral Corp. (OTCBB:RBCC), an emerging biotechnology company, is hard at work identifying and targeting promising new stem-cell treatments for commercialization.
PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc.- Florida has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Watson's generic versions of Mallinckrodt's Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets. Mallinckrodt filed its lawsuit on December 10, 2010 in the United States District Court for the District of New Jersey following Watson's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its product in the 8 mg, 12 mg, and 16 mg dosage strengths.Under terms of the settlement agreement, Mallinckrodt has granted Watson a royalty-free license to U.S. patents relating to Exalgo®. Watson will have the right to launch its bioequivalent products on November 15, 2013. Other details of the settlement were not disclosed.
Rainbow BioSciences, a division of Rainbow Coral Corp. (OTCBB: RBCC), is staying connected in the center of advanced bio-research in Houston.
RSS|
My Yahoo|
Newsletters|
Mobile|
Alerts|
Twitter
Terms of Service| Privacy Policy| About our ads| Copyright| About The Miami Herald| About the McClatchy Company| Corrections| Contact Us| Advertise| Work for Us
Partners: El Nuevo Herald| Newspaper in Education| WLRN | Miami Herald News| CBS4 WFOR-TV| More
Copyright 2012 Miami Herald Media Co. All rights reserved
